Brief: Lipigon Announces Positive Results From Preparatory Preclinical Safety Study For Lipid-Lowering Drug Candidate Lipisense

Lipigon Pharmaceuticals AB

10/09/2021 08:35

Sept 10 (Reuters) - Lipigon Pharmaceuticals AB  LPGO.ST :
    * LIPIGON ANNOUNCES POSITIVE RESULTS FROM PREPARATORY
PRECLINICAL
SAFETY STUDY FOR LIPID-LOWERING DRUG CANDIDATE LIPISENSE
    * RESULT OF STUDY SHOWS NO SAFETY CONCERNS WITH DOSES UP TO
30MG/KG.
    * FURTHERMORE, A DOSE-DEPENDENT DECREASE OF PLASMA
TRIGLYCERIDE
LEVELS BY 30-50% WAS OBSERVED.
    * DEVELOPMENT FOLLOWS PLAN AND WE CONFIDENTLY LOOK FORWARD
TO
FUTURE STUDY RESULTS AND CLINICAL TRIALS THAT ARE EXPECTED TO
BEGIN DURING FIRST HALF OF 2022
    * SUBMISSION OF A CLINICAL TRIAL APPLICATION IS ESTIMATED TO
Q1
2022, AND START OF PHASE I STUDY IS ESTIMATED TO Q2 2022

Source text for Eikon:  ID:nBQN4Dkzlx 
Further company coverage:  LPGO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))